Latest / Flash Stock Reports (Video)
LENZ: Inside the $220M Biotech Burning Below Cash
LENZ stock analysis: trading at -$40M EV signals a massive market disconnect — deep dive
👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_video&utm_medium=explainer_video&utm_campaign=freja_and_friends
In this deep dive, we break down LENZ Therapeutics Inc (LENZ) and the market launch of VIZZ, their FDA-approved eye drop for presbyopia. With its enterprise value trading at a negative $40 million despite a $220 million cash cushion, the key question for investors is whether flat domestic sales will deplete…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.